Digital twins enable faster recruitment with higher powered, individualized trials [capable of generating] additional data from the same or fewer number of patients.
Here, we have demonstrated that a particular type of generative model (i.e., CRBMs) can be used to accurately model disease progression for patients with MCI or AD.
To solve the problem of trial inefficiency, clinical trial sponsors are turning to external data sources to supplement and increase efficiency of clinical trials.
